Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: CareDx; Proteomics International; Pangea Laboratory

NEW YORK –  CareDx said this week that it is offering its Transplant Pharmacy services to patient members of the National Foundation for Transplants in an effort to help them better manage post-transplant medication adherence. The company's Transplant Pharmacy team helps patients coordinate benefits to reduce out-of-pocket costs and helps ensure that patients receive regular personalized care. 

Proteomics International Laboratories (PIL) this week said it has signed a five-year licensing agreement with longtime partner Omics Global Solutions to make PIL's PromarkerD predictive test for diabetic kidney disease available in Chile. The agreement also includes royalties based on sales of the test, which Omics manufactures under license. Omics will market the test initially to Chile's private payor market and eventually expand into other markets in Central and South America. PromarkerD measures three serum protein biomarkers, combined with routinely available conventional clinical variables (age, HDL cholesterol, and estimated glomerular filtration rate) to predict future kidney function decline in patients with type 2 diabetes and no existing diabetic kidney disease. 

Pangea Laboratory said this week that the US Food and Drug Administration has granted breakthrough device designation for the firm's molecular assay for detection of bladder cancer and upper tract urothelial carcinoma. The Tustin, California-based company's Bladder Care Assay is a urine-based qPCR test that is used in patients with hematuria for quantitative detection of DNA methylation biomarkers. The firm said its study results indicate the assay detects bladder cancer with 94 percent sensitivity and 93 percent specificity, upper tract urothelial carcinoma with 96 percent sensitivity and 88 percent specificity, and carcinoma in situ with 89 percent sensitivity. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.